Immunic Inc. (IMUX)

Name: Immunic Inc. (IMUX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Immunic Inc. (IMUX)

Stock Card

$15.55

$-0.26 (-1.61%)

As on 01-Sep-2026 10:35EDT

Market cap

$210 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.7

Div. Yield

0 %

Immunic (IMUX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 15.35 High: 16.10

52 Week Range

Low: 5.06 High: 92.05

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.2
Debt to Equity

0
Book Value

$--
EPS

$-4.8
Face value

--
Shares outstanding

13,644,467

10 Years Aggregate

CFO

$-503.99 Mln

EBITDA

$-555.31 Mln

Net Profit

$-653.70 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Immunic (IMUX)	191.3	11.3	3.9	89.6	-2.4	-30.9	-39.3
BSE Sensex	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Immunic (IMUX)	-46.6	-33.1	7.1	-85.4	-37.4	57.6	30.2
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Immunic (IMUX)	15.5	210.1	0.0	-111.6	--	--	--	1.7
Arrowhead Pharmaceuticals (ARWR)	82.5	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	261.6	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	70.8	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	55.4	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	107.2	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	360.7	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	540.0	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	585.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	353.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Immunic (IMUX)

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is... in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. Read more

Executive Chairman

Dr. Duane D. Nash J.D., M.B.A., M.D.
Executive Chairman

Dr. Duane D. Nash J.D., M.B.A., M.D.
Headquarters

New York, NY
Website

https://imux.com

FAQs for Immunic (IMUX)

What is the current share price of Immunic Inc (IMUX) Today?

The share price of Immunic Inc (IMUX) is $15.55 (NASDAQ) as of 01-Sep-2026 10:35 EDT. Immunic Inc (IMUX) has given a return of -2.36% in the last 3 years.

What is the current PB & PE ratio of Immunic Inc (IMUX)?

Since, TTM earnings of Immunic Inc (IMUX) is negative, P/E ratio is not available.
The P/B ratio of Immunic Inc (IMUX) is 1.74 times as on 28-Aug-2026, a 66 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.